Investigational Drug Information for ISV-305
✉ Email this page to a colleague
What is the development status for investigational drug ISV-305?
ISV-305 is an investigational drug.
There have been 15 clinical trials for ISV-305.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 3rd 2020.
The most common disease conditions in clinical trials are Cataract, Inflammation, and Conjunctivitis, Bacterial. The leading clinical trial sponsors are InSite Vision, Sun Pharma Global FZE, and Bausch & Lomb Incorporated.
There are seven hundred and forty-four US patents protecting this investigational drug and thirty-six international patents.
Summary for ISV-305
| US Patents | 744 |
| International Patents | 36,669 |
| US Patent Applications | 4,639 |
| WIPO Patent Applications | 2,670 |
| Japanese Patent Applications | 23 |
| Clinical Trial Progress | Phase 3 (2020-04-03) |
| Vendors | 76 |
Recent Clinical Trials for ISV-305
| Title | Sponsor | Phase |
|---|---|---|
| Rib Fracture Analgesia Using Cryoanalgesia | Epimed International | Phase 4 |
| Rib Fracture Analgesia Using Cryoanalgesia | University of Florida | Phase 4 |
| Rib Fracture Analgesia Using Cryoanalgesia | University of California, San Diego | Phase 4 |
Clinical Trial Summary for ISV-305
Top disease conditions for ISV-305
Top clinical trial sponsors for ISV-305
US Patents for ISV-305
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ISV-305 | See Plans and Pricing | Phosphonate compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | See Plans and Pricing |
| ISV-305 | See Plans and Pricing | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | Seattle Genetics, Inc. (Bothell, WA) | See Plans and Pricing |
| ISV-305 | See Plans and Pricing | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | See Plans and Pricing |
| ISV-305 | See Plans and Pricing | Use of inhibitors of Bruton'S tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | See Plans and Pricing |
| ISV-305 | See Plans and Pricing | Method for differentially diagnosing ACTH-dependent cushing's syndrome | Corcept Therapeutics, Inc. (Menlo Park, CA) | See Plans and Pricing |
| ISV-305 | See Plans and Pricing | Tapered looped suture | Covidien LP (Mansfield, MA) | See Plans and Pricing |
| ISV-305 | See Plans and Pricing | Methods of treating cancer patients with farnesyltransferase inhibitors | Kura Oncology, Inc. (La Jolla, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ISV-305
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ISV-305 | Taiwan | TW201718611 | 2035-08-26 | See Plans and Pricing |
| ISV-305 | World Intellectual Property Organization (WIPO) | WO2017035357 | 2035-08-26 | See Plans and Pricing |
| ISV-305 | European Patent Office | EP2556083 | 2030-04-05 | See Plans and Pricing |
| ISV-305 | World Intellectual Property Organization (WIPO) | WO2011127048 | 2030-04-05 | See Plans and Pricing |
| ISV-305 | Australia | AU2006269422 | 2025-07-07 | See Plans and Pricing |
| ISV-305 | Canada | CA2614436 | 2025-07-07 | See Plans and Pricing |
| ISV-305 | European Patent Office | EP1917020 | 2025-07-07 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
